Inhibition of the PD-1/PD-L1 pathway through the administration of monoclonal antibodies (mAbs) has the potential to reactivate the function of cytotoxic T lymphocytes (CTLs) and their capacity to attack tumor cells (139). Here, PDCD1 is linked to neoplasm.